Blaze Bioscience

Blaze Bioscience, Inc., founded in Seattle, is a privately held biotechnology company with a mission to improve the lives of cancer patients, particularly children undergoing brain cancer surgery. The company's core technology, Tumor Paint®, along with the CANVAS® imaging system, provides real-time, high-resolution intraoperative visualization of cancer cells. This technology aims to make the detection, removal, and treatment of cancers more sensitive, reliable, and accessible, especially for early-stage cancers where a cure is still possible.

Notable figures affiliated with Blaze Bioscience include its founders and key investors who have supported its innovative approach to cancer treatment. The company has achieved significant milestones in developing and commercializing its Tumor Paint® technology, which has the potential to revolutionize surgical oncology by enabling more precise and complete resection of cancerous tissues. Blaze Bioscience's impact is profound, offering hope for improved surgical outcomes and better quality of life for cancer patients.